Company news
NextCure, Inc. news in 2022
NextCure, Inc.'s news releases, calls and decks from 2022, newest first.
NextCure and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates
November 14, 2022
NextCure Provides Update and Reports Third Quarter 2022 Financial Results
November 2, 2022
NextCure Appoints Dr. Lisa M. Coussens to Scientific Advisory Board
October 26, 2022
NextCure Announces Initiation of Phase 1b/2 Clinical Trial to Evaluate NC410 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Immune Checkpoint Refractory or Naïve Solid Tumors
October 3, 2022
NextCure Provides Business Update and Reports Second Quarter 2022 Financial Results
August 3, 2022
NextCure Announces Development of a Highly Specific Immunohistochemical Diagnostic for Siglec-15-positive Tumors as reported in Laboratory Investigation
July 5, 2022
Dr. Brahm Segal appointed to NextCure Scientific Advisory Board; NextCure and Roswell Park Shared Nonclinical Data on the Impact of NC410 Blockade on Neutrophil-mediated T Cell Suppression at the 24th Translational Research Cancer Centers Consortium A...
June 21, 2022
NextCure Provides Business Update and Reports First Quarter 2022 Financial Results
May 4, 2022
NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
March 2, 2022
Decks in 2022
- Investor Presentation (March 2022)
Investor deck · 27 slides · Mar 3, 2022